Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Ji Min | - |
dc.contributor.author | Kim, Yoon Jae | - |
dc.contributor.author | Lee, Kang-Moon | - |
dc.contributor.author | Yoon, Hyuk | - |
dc.contributor.author | Lee, Bo-In | - |
dc.contributor.author | Kim, Dae Bum | - |
dc.contributor.author | Kang, Donghoon | - |
dc.date.available | 2020-02-27T08:41:55Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2018-11-02 | - |
dc.identifier.issn | 0036-5521 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/3078 | - |
dc.description.abstract | Objectives: We investigated the long-term clinical outcome and risk factors for clinical relapse in inflammatory bowel disease (IBD) patients after stopping infliximab (IFX). Materials and methods: We retrospectively reviewed the medical records of IBD patients who were treated with IFX in four university hospitals in South Korea. Among them, patients who discontinued scheduled IFX therapy with a favorable disease course were enrolled. Clinical relapse was defined as an increase in disease activity, addition of new drugs, or abdominal surgery. Results: In total, 28 ulcerative colitis (UC) patients and 17 Crohn's disease (CD) patients were enrolled. The median duration of follow-up after discontinuation was 41 months (range: 8-109 months) in UC patients and 141 months (range: 66-262 months) in CD patients. The cumulative probability of relapse at 12 months was 32.1% in UC patients and 30.7% in CD patients. Fewer IFX infusions and a shorter duration of mesalamine treatment after IFX discontinuation were risk factors for relapse after IFX discontinuation in UC patients (p = .04 and .01, respectively). In CD patients, a higher erythrocyte sedimentation rate and CRP at IFX discontinuation and a shorter duration of azathioprine treatment after IFX discontinuation were risk factors for relapse (p = .03, .03 and .01, respectively). Conclusions: Approximately 30% of IBD patients who responded to IFX therapy experienced relapse within 1 year after discontinuation. We identified several risk factors for relapse. Further studies should identify factors predictive of the disease course after discontinuing IFX maintenance therapy. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.relation.isPartOf | SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY | - |
dc.subject | CROHNS-DISEASE | - |
dc.subject | FOLLOW-UP | - |
dc.subject | MAINTENANCE THERAPY | - |
dc.subject | ULCERATIVE-COLITIS | - |
dc.subject | MULTICENTER | - |
dc.subject | MANAGEMENT | - |
dc.subject | REMISSION | - |
dc.subject | CONSENSUS | - |
dc.title | Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000457980900019 | - |
dc.identifier.doi | 10.1080/00365521.2018.1524024 | - |
dc.identifier.bibliographicCitation | SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, v.53, no.10-11, pp.1280 - 1285 | - |
dc.identifier.scopusid | 2-s2.0-85055555087 | - |
dc.citation.endPage | 1285 | - |
dc.citation.startPage | 1280 | - |
dc.citation.title | SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY | - |
dc.citation.volume | 53 | - |
dc.citation.number | 10-11 | - |
dc.contributor.affiliatedAuthor | Kim, Yoon Jae | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Infliximab | - |
dc.subject.keywordAuthor | discontinuation | - |
dc.subject.keywordAuthor | inflammatory bowel disease | - |
dc.subject.keywordAuthor | relapse | - |
dc.subject.keywordPlus | CROHNS-DISEASE | - |
dc.subject.keywordPlus | FOLLOW-UP | - |
dc.subject.keywordPlus | MAINTENANCE THERAPY | - |
dc.subject.keywordPlus | ULCERATIVE-COLITIS | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | REMISSION | - |
dc.subject.keywordPlus | CONSENSUS | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.